Roch Pharmaceutical has granted a license for its proprietary drug, Tacitup, to Vor Bio, a U.S.-based firm, in exchange for compensation. Under the agreement, Vor Bio will hold exclusive global rights to develop, manufacture, and market the drug outside of Greater China. According to the deal terms, Roch Pharmaceutical will receive an initial payment of $125 million in cash and warrants, with the potential to earn up to $4.105 billion through milestone payments and sales royalties. Despite Roch Pharmaceutical's assertion in its announcement that the deal aligns with market potential and leverages its business model's strengths, the market response has been disappointing, with the stock price plummeting. Analysts attribute the sharp decline in stock price primarily to the relatively modest upfront payment. Furthermore, Roch Pharmaceutical reported a nearly 60% year-over-year increase in revenue for the first quarter of 2025, highlighted by significant growth in core product sales.